Fresenius Medical Care 将来の成長

Future 基準チェック /26

Fresenius Medical Care利益と収益がそれぞれ年間19.3%と3.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に7.7% 18%なると予測されています。

主要情報

19.3%

収益成長率

18.0%

EPS成長率

Healthcare 収益成長	24.7%
収益成長率	3.8%
将来の株主資本利益率	7.7%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BRSE:FME - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	20,632	1,103	1,878	2,713	16
12/31/2025	19,870	937	1,956	2,562	18
12/31/2024	19,257	678	1,783	2,572	18
9/30/2024	19,239	659	1,538	2,274	N/A
6/30/2024	19,415	530	1,342	2,049	N/A
3/31/2024	19,474	484	1,911	2,613	N/A
12/31/2023	19,454	499	1,918	2,629	N/A
9/30/2023	19,463	450	1,799	2,509	N/A
6/30/2023	19,622	596	1,674	2,407	N/A
3/31/2023	19,554	602	1,401	2,152	N/A
12/31/2022	19,398	673	1,397	2,167	N/A
9/30/2022	19,048	763	1,444	2,237	N/A
6/30/2022	18,393	806	1,444	2,271	N/A
3/31/2022	17,957	878	1,576	2,441	N/A
12/31/2021	17,619	969	1,603	2,489	N/A
9/30/2021	17,372	918	1,477	2,405	N/A
6/30/2021	17,344	998	1,480	2,459	N/A
3/31/2021	17,581	1,131	2,869	3,857	N/A
12/31/2020	17,859	1,164	3,148	4,233	N/A
9/30/2020	18,039	1,330	3,299	4,420	N/A
6/30/2020	18,044	1,309	3,377	4,542	N/A
3/31/2020	17,832	1,212	1,832	3,075	N/A
12/31/2019	17,477	1,200	1,404	2,567	N/A
9/30/2019	17,196	1,282	1,367	2,494	N/A
6/30/2019	16,835	1,234	1,246	2,379	N/A
3/31/2019	16,704	1,974	1,065	2,182	N/A
12/31/2018	16,547	1,982	920	2,062	N/A
9/30/2018	16,676	1,951	766	1,892	N/A
6/30/2018	16,954	1,975	N/A	1,750	N/A
3/31/2018	17,211	1,250	N/A	1,977	N/A
12/31/2017	17,784	1,280	N/A	2,192	N/A
9/30/2017	17,771	1,249	N/A	2,436	N/A
6/30/2017	17,647	1,244	N/A	2,217	N/A
3/31/2017	17,201	1,239	N/A	1,938	N/A
12/31/2016	16,570	1,144	N/A	1,932	N/A
9/30/2016	16,101	1,063	N/A	1,648	N/A
6/30/2016	15,841	998	N/A	1,782	N/A
3/31/2016	15,402	933	N/A	1,491	N/A
12/31/2015	15,455	955	N/A	1,767	N/A
9/30/2015	15,345	939	N/A	1,791	N/A
6/30/2015	15,246	948	N/A	1,914	N/A
3/31/2015	15,428	977	N/A	2,044	N/A
12/31/2014	13,329	864	N/A	1,538	N/A
9/30/2014	12,413	839	N/A	1,476	N/A
6/30/2014	11,112	775	N/A	1,283	N/A
3/31/2014	10,882	791	N/A	1,329	N/A
12/31/2013	10,816	806	N/A	1,478	N/A

アナリストによる今後の成長予測

収入対貯蓄率: FMEの予測収益成長率 (年間19.3% ) は貯蓄率 ( 0.3% ) を上回っています。

収益対市場: FMEの収益 ( 19.3% ) はSwiss市場 ( 11% ) よりも速いペースで成長すると予測されています。

高成長収益: FMEの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: FMEの収益 ( 3.8% ) Swiss市場 ( 4.3% ) よりも低い成長が予測されています。

高い収益成長: FMEの収益 ( 3.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: FMEの自己資本利益率は、3年後には低くなると予測されています ( 7.7 %)。

Fresenius Medical Care 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024

Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024

Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024

Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023

Recent updates

Fresenius Medical Care AG to Report Q2, 2025 Results on Aug 05, 2025

Fresenius Medical Care AG to Report Q1, 2025 Results on May 06, 2025

Fresenius Medical Care AG to Report Q4, 2024 Results on Feb 25, 2025

Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: €0.64 (vs €0.48 in 2Q 2023)

Upcoming dividend of €1.19 per share

New minor risk - Financial position

First quarter 2024 earnings released: EPS: €0.24 (vs €0.29 in 1Q 2023)

Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024

Dividend of €1.19 announced

Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device

Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024

Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023

Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023

Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024

Fresenius Medical Care Brings Dialysis Therapy to Kidney Disease Patients in the U.S

Fresenius Medical Care Enters into Favorable Settlement Agreement with U. S. Government

Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023

Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 22, 2024

An Unknown buyer entered into an agreement to acquire National Cardiovascular Partners, LP from Fresenius Medical Care AG & Co. KGaA (XTRA:FME)

Fresenius Medical Care AG & Co. KGaA to Report Q1, 2024 Results on May 07, 2024

Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery

Fresenius Medical Care Achieves Key Ai Milestone with First-Phase Completion of Largest Global Dialysis Clinical Dataset

Investor sentiment deteriorates as stock falls 24%

Fresenius Medical Care Announces Fda Clearance of Versi(R)Hd with Guideme Software

An unknown buyer acquired Local dialysis service provider business from Fresenius Medical Care AG & Co. KGaA (XTRA:FME).

Fresenius Medical Care Announces Executive Changes

Fresenius Medical Care participated Announces Breakthrough Study Demonstrates That High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates

Upcoming dividend of €1.12 per share at 2.5% yield

Investor sentiment improves as stock rises 17%

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘